Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

Danish (OMX) Healthcare Sector Analysis

UpdatedMar 15, 2026
DataAggregated Company Financials
Companies21
  • 7D-0.8%
  • 3M-20.9%
  • 1Y-47.2%
  • YTD-23.1%

The Healthcare is pretty flat in the last 7 days, but Zealand Pharma has stood out, gaining 14%. Unfortunately though, the industry is down 47% over the past 12 months. As for the next few years, earnings are expected to grow by 5.8% per annum.

Sector Valuation and Performance

Has the Danish Healthcare Sector valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Sun, 15 Mar 2026DKK 1.5tDKK 448.1bDKK 130.1b16.8x11.6x3.4x
Tue, 10 Feb 2026DKK 1.8tDKK 448.0bDKK 134.8b16.3x13.6x4.1x
Thu, 08 Jan 2026DKK 2.1tDKK 453.9bDKK 136.9b17.6x15.6x4.7x
Sat, 06 Dec 2025DKK 1.9tDKK 454.0bDKK 137.0b17.3x13.8x4.1x
Mon, 03 Nov 2025DKK 1.9tDKK 448.0bDKK 141.9b17.2x13.4x4.3x
Wed, 01 Oct 2025DKK 2.0tDKK 447.3bDKK 141.7b17.6x14.2x4.5x
Fri, 29 Aug 2025DKK 2.1tDKK 447.4bDKK 141.7b24.5x14.6x4.6x
Sun, 27 Jul 2025DKK 2.5tDKK 423.1bDKK 124.5b30.1x19.9x5.9x
Tue, 24 Jun 2025DKK 2.5tDKK 423.4bDKK 124.6b30.4x19.7x5.8x
Thu, 22 May 2025DKK 2.5tDKK 424.3bDKK 125.1b24.1x19.9x5.9x
Sat, 19 Apr 2025DKK 2.3tDKK 409.2bDKK 121.3b21.8x19.1x5.7x
Mon, 17 Mar 2025DKK 2.8tDKK 409.5bDKK 121.3b24.9x23.5x7x
Wed, 12 Feb 2025DKK 3.2tDKK 408.3bDKK 118.3b28.1x27.1x7.8x
Fri, 10 Jan 2025DKK 3.4tDKK 387.5bDKK 111.3b30.3x30.1x8.6x
Sun, 08 Dec 2024DKK 4.0tDKK 387.3bDKK 111.3b31.3x36.3x10.4x
Tue, 05 Nov 2024DKK 3.9tDKK 372.2bDKK 107.2b33.2x36.5x10.5x
Thu, 03 Oct 2024DKK 4.1tDKK 372.0bDKK 107.1b36.3x38.4x11.1x
Sat, 31 Aug 2024DKK 4.8tDKK 371.8bDKK 107.1b35.5x44.7x12.9x
Mon, 29 Jul 2024DKK 4.5tDKK 355.4bDKK 106.3b35.9x42.1x12.6x
Wed, 26 Jun 2024DKK 5.1tDKK 355.3bDKK 106.2b34.3x48.3x14.5x
Fri, 24 May 2024DKK 4.7tDKK 355.3bDKK 106.2b37.6x44.6x13.3x
Sun, 21 Apr 2024DKK 4.4tDKK 341.3bDKK 99.6b33.3x44.5x13x
Tue, 19 Mar 2024DKK 4.7tDKK 341.2bDKK 99.6b39.2x46.9x13.7x
Thu, 15 Feb 2024DKK 4.3tDKK 340.5bDKK 98.6b34.9x44x12.7x
Sat, 13 Jan 2024DKK 3.8tDKK 320.5bDKK 90.0b33.5x42x11.8x
Mon, 11 Dec 2023DKK 3.5tDKK 320.6bDKK 90.0b33.8x38.9x10.9x
Wed, 08 Nov 2023DKK 3.6tDKK 318.7bDKK 90.3b29.3x40.2x11.4x
Fri, 06 Oct 2023DKK 3.3tDKK 305.5bDKK 82.2b32.7x40.7x11x
Sun, 03 Sep 2023DKK 3.5tDKK 305.4bDKK 82.2b36.7x42x11.3x
Tue, 01 Aug 2023DKK 3.0tDKK 287.2bDKK 75.5b37.6x39.7x10.4x
Thu, 29 Jun 2023DKK 2.9tDKK 287.1bDKK 75.5b39.1x38.3x10.1x
Sat, 27 May 2023DKK 3.1tDKK 287.2bDKK 75.5b41.8x41.4x10.9x
Mon, 24 Apr 2023DKK 3.2tDKK 272.6bDKK 68.5b44x46.7x11.7x
Wed, 22 Mar 2023DKK 2.8tDKK 292.5bDKK 69.2b37.9x40.5x9.6x
Price to Earnings Ratio

40.5x


Total Market Cap: DKK 2.8tTotal Earnings: DKK 69.2bTotal Revenue: DKK 292.5bTotal Market Cap vs Earnings and Revenue0%0%0%
Danish Healthcare Sector Price to Earnings3Y Average 32.3x202420252026
Current Industry PE
  • Investors are pessimistic on the Danish Healthcare industry, indicating that they anticipate long term growth rates will be lower than they have historically.
  • The industry is trading at a PE ratio of 11.6x which is lower than its 3-year average PE of 32.3x.
  • The 3-year average PS ratio of 9.2x is higher than the industry's current PS ratio of 3.4x.
Past Earnings Growth
  • The earnings for companies in the Healthcare industry have grown 23% per year over the last three years.
  • Revenues for these companies have grown 15% per year.
  • This means that more sales are being generated by these companies overall, and subsequently their profits are increasing too.

Industry Trends

Which industries have driven the changes within the Danish Healthcare sector?

DK Market-1.27%
Healthcare-0.76%
Healthtech3.10%
Biotech0.48%
Pharma-0.59%
Life Sciences-2.64%
Medical Equipment-2.78%
Healthcare Services-4.01%
Industry PE
  • Investors are most optimistic about the Healthcare Services industry which is trading above its 3-year average PE ratio of 448x.
    • Analysts are expecting annual earnings growth of 85.3%, which is higher than its past year's earnings decline of 99.7% per year.
Forecasted Growth
  • Analysts are most optimistic on the Healthcare Services industry, expecting annual earnings growth of 85% over the next 5 years.
  • This is better than its past earnings decline of 100% per year.
  • In contrast, the Life Sciences industry is expected to see its earnings growth to stay flat over the next few years.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
ZEAL Zealand PharmaDKK 268.2014.2%
+DKK 2.4b		-54.2%PE2.9x
DEMANT DemantDKK 188.100.3%
+DKK 126.5m		-24.5%PE16.8x
NNIT NNITDKK 41.203.0%
+DKK 29.9m		-43.7%PS0.6x
STRAP Strategic PartnersDKK 642.0010.7%
+DKK 2.6m		-9.7%PB1.5x
BRAINP Brain+DKK 0.00578.6%
+DKK 2.5m		-86.3%PS1x

Latest News

COLO B
DKK 447.40
Coloplast
7D
-3.1%
1Y
-38.4%
NNIT
DKK 41.20
NNIT
7D
3.0%
1Y
-43.7%
HLUN B
DKK 37.52
H. Lundbeck
7D
-0.7%
1Y
-4.5%
ALK B
DKK 209.40
ALK-Abelló
7D
-5.9%
1Y
46.9%

ALK B: Future Upside Will Rely On Wider Anaphylaxis Treatment Adoption

Analysts have kept their DKK 255.00 price target for ALK-Abelló unchanged, indicating that their views on fair value, discount rate, expected revenue growth, profit margin and future P/E assumptions remain broadly steady. What's in the News ALK-Abelló presented late-breaking data from a 90-participant study comparing needle-free EURneffy nasal adrenaline to injectable auto-injectors for anaphylaxis, with 88% of participants preferring EURneffy, mainly for ease of use, portability and the absence of a needle (AAAAI 2026 Annual Meeting).
DEMANT
DKK 188.10
Demant
7D
0.3%
1Y
-24.5%

DEMANT: Recent Upgrade And 2026 Guidance May Support Further Upside

Our updated narrative keeps the fair value estimate steady at DKK 232.17 per share, reflecting a balanced view of recent Street research. One analyst raised Demant to a Buy with a DKK 230 target, while several others trimmed their price targets.
EMBLA
DKK 27.60
Embla Medical hf
7D
-6.8%
1Y
-5.2%

EMBLA: Share Cancellations And New Capital Authorisations Will Support Future Upside

Analysts have kept their DKK 37.40 price target for Embla Medical hf unchanged. They cite only minor tweaks to the discount rate, revenue growth, profit margin and future P/E assumptions that do not materially alter their view of fair value.
ZEAL
DKK 268.20
Zealand Pharma
7D
14.2%
1Y
-54.2%

ZEAL: Petrelintide Obesity Data And Pipeline Progress Will Support Future Upside

The updated analyst price target for Zealand Pharma moves lower to DKK 611 from about DKK 730, as analysts factor in reduced expectations for petrelintide's obesity opportunity, modestly higher risk assumptions, and a lower implied future P/E multiple, following a series of rating downgrades to Neutral or Hold. Analyst Commentary Recent research notes cluster around a more cautious stance on Zealand Pharma, with several firms shifting ratings to Neutral or Hold and setting price targets below the prior DKK 730 level.
AMBU B
DKK 71.90
Ambu
7D
-5.0%
1Y
-40.3%

AMBU B: Share Repurchase Mandate And Lowered Fair Value Will Support Upside

Analysts have trimmed their price target on Ambu by DKK 12 to reflect updated assumptions on fair value, discount rates and earnings expectations following recent research commentary. Analyst Commentary Bullish Takeaways Bullish analysts view the revised DKK 12 lower price target as still consistent with a supportive fair value range.
NOVO B
DKK 247.05
Novo Nordisk
7D
-0.3%
1Y
-53.4%

NOVO B: Future Returns Will Rely On Oral Obesity And GLP-1 Tablet Expansion

The updated analyst price target for Novo Nordisk has shifted from DKK 376.59 to DKK 330.95, with analysts citing more measured assumptions on revenue growth, profit margins and future P/E as key drivers of the change. Analyst Commentary Analysts revisiting their assumptions on Novo Nordisk are effectively marking the shares to more conservative expectations, with the updated price target of DKK 330.95 reflecting a reset in what they are willing to pay for the company’s earnings profile.
CHEMM
DKK 399.60
ChemoMetec
7D
-3.5%
1Y
-24.9%
GMAB
DKK 1,702.50
Genmab
7D
-1.5%
1Y
20.4%

GMAB: 2026 Catalyst Events And AI Adoption Will Shape Outlook

Genmab's analyst fair value estimate has moved up from DKK 2,182 to DKK 2,238, as analysts factor in higher long term revenue growth assumptions, a higher future P/E and recent price target revisions around DKK 2,400 to DKK 2,500, even as they temper near term expectations for Epkinly and margins. Analyst Commentary Recent research points to a more nuanced view of Genmab, with several firms adjusting their price targets and models following the latest earnings, product updates and acquisition activity.
PEG
DKK 0.096
Pharma Equity Group
7D
1.1%
1Y
-32.1%
BRAINP
DKK 0.005
Brain+
7D
78.6%
1Y
-86.3%
STRAP
DKK 642.00
Strategic Partners
7D
10.7%
1Y
-9.7%